Business Description
Traws Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US68232V3069
Description
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -0.23 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -148.1 | |||||
| Beneish M-Score | 108.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -18.6 | |||||
| 3-Year EBITDA Growth Rate | 23.5 | |||||
| 3-Year EPS without NRI Growth Rate | 25.3 | |||||
| 3-Year FCF Growth Rate | 24.6 | |||||
| 3-Year Book Growth Rate | 0.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 63.57 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.37 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.82 | |||||
| 9-Day RSI | 31.94 | |||||
| 14-Day RSI | 35.09 | |||||
| 6-1 Month Momentum % | -55.25 | |||||
| 12-1 Month Momentum % | -54.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.07 | |||||
| Quick Ratio | 1.07 | |||||
| Cash Ratio | 0.65 | |||||
| Days Sales Outstanding | 708.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -10661.06 | |||||
| Net Margin % | -62294.25 | |||||
| FCF Margin % | -13345.41 | |||||
| ROA % | -736.98 | |||||
| ROIC % | -2598.58 | |||||
| ROC (Joel Greenblatt) % | -130945.65 | |||||
| ROCE % | -246.15 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 19.52 | |||||
| EV-to-EBIT | -0.39 | |||||
| EV-to-Forward-EBIT | -0.01 | |||||
| EV-to-EBITDA | -0.39 | |||||
| EV-to-Forward-EBITDA | -0.01 | |||||
| EV-to-Revenue | 42.09 | |||||
| EV-to-Forward-Revenue | 1.04 | |||||
| EV-to-FCF | -0.3 | |||||
| Price-to-Median-PS-Value | 0.83 | |||||
| Earnings Yield (Greenblatt) % | -256.36 | |||||
| FCF Yield % | -198.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Traws Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.207 | ||
| EPS (TTM) (€) | -131.066 | ||
| Beta | 1.36 | ||
| Volatility % | 54.52 | ||
| 14-Day RSI | 35.09 | ||
| 14-Day ATR (€) | 0.004739 | ||
| 20-Day SMA (€) | 6.6 | ||
| 12-1 Month Momentum % | -54.09 | ||
| 52-Week Range (€) | 6.6 - 29.75 | ||
| Shares Outstanding (Mil) | 3.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Traws Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Traws Pharma Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Traws Pharma Inc Frequently Asked Questions
What is Traws Pharma Inc(FRA:0T20)'s stock price today?
The current price of FRA:0T20 is €6.60. The 52 week high of FRA:0T20 is €29.75 and 52 week low is €6.60.
When is next earnings date of Traws Pharma Inc(FRA:0T20)?
The next earnings date of Traws Pharma Inc(FRA:0T20) is 2025-02-14 Est..
Does Traws Pharma Inc(FRA:0T20) pay dividends? If so, how much?
Traws Pharma Inc(FRA:0T20) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers